While anti-PD-1/PD-L1 monoclonal antibodies have been clinically approved for treating multiple malignancies and have exhibited promising anti-tumor effects in some patients, the low objective response rate of patients remains a challenge (6). The gene discussed is PDCD1; the disease is neoplasm.